The double lives of phosphatases of regenerating liver: A structural view of their catalytic and noncatalytic activities

Kalle Gehring, Guennadi Kozlov, Meng Yang, and Rayan Fakih

From the Department of Biochemistry and Centre de Recherche en Biologie Structurale, McGill University, Montreal, Quebec, Canada

Edited by Wolfgang Peti

Phosphatases of regenerating liver (PRLs) are protein phosphatases involved in the control of cell growth and migration. They are known to promote cancer metastasis but, despite over 20 years of study, there is still no consensus about their mechanism of action. Recent work has revealed that PRLs lead double lives, acting both as catalytically active enzymes and as pseudophosphatases. The three known PRLs belong to the large family of cysteine phosphatases that form a phosphocysteine intermediate during catalysis. Uniquely to PRLs, this intermediate is stable, with a lifetime measured in hours. As a consequence, PRLs have very little phosphatase activity. Independently, PRLs also act as pseudophosphatases by binding CNNM membrane proteins to regulate magnesium homeostasis. In this function, an aspartic acid from CNNM inserts into the phosphatase catalytic site of PRLs, mimicking a substrate–enzyme interaction. The delineation of PRL pseudophosphatase and phosphatase activities in vivo was impossible until the recent identification of PRL mutants defective in one activity or the other. These mutants showed that CNNM binding was sufficient for PRL oncogenicity in one model of metastasis, but left unresolved its role in other contexts. As the presence of phosphocysteine prevents CNNM binding and CNNM-binding blocks catalytic activity, these two activities are inherently linked. Additional studies are needed to untangle the intertwined catalytic and noncatalytic functions of PRLs. Here, we review the current understanding of the structure and biophysical properties of PRL phosphatases.

PRLs are members of CBP superfamily

The three mammalian PRLs are highly related in their amino acid sequences. PRL-1 and PRL-2 are the most similar with 88% identity while PRL-1 and PRL-3 share 79% identity. The proteins are classified as class IVa protein tyrosine phosphatases, leading to their gene designations: PTP4A1, PTP4A2, and PTP4A3. The phosphatases are often considered to be DUSPs, which are phosphatases that act on both phosphotyrosine and phosphothreonine/serine. Among CBPs, the PRL phosphatases are most similar to cell division cycle 14 (CDC14) phosphatases and share approximately 30% sequence identity. Structurally, they consist of a single catalytic domain followed by an unfolded C-terminal tail of ~20-residues capped with a CAAX farnesylation motif (Fig. 1A). Among protein phosphatases, the C-terminal farnesylation is unique to PRLs and serves to localize them to cellular membranes including the plasma membrane (5–9).

PRL function

PRLs have been implicated in a wide variety of cellular functions. In mammals, PRLs appear to be primarily involved in regulation of cell proliferation and migration. PRL-1 and -2 have broad tissue distributions while PRL3 is normally largely restricted to muscle (10). Much of the interest in PRLs arises from their overexpression in cancer. PRL-3 is highly upregulated in metastatic colon cancer and is associated with poor prognosis in many types of cancer (11). PRL-1 and PRL-2 overexpression is less prevalent in human cancers, but they include a small number of pseudophosphatases, which have lost their catalytic activity through evolution and act through the direct binding of proteins.

* For correspondence: Kalle Gehring, kalle.gehring@mcgill.ca,
have been shown to be oncogenic in cell and animal model systems (reviewed in (10, 12)).

The genetic knockout of the PRLs is viable in mice (13–17). This is likely due to complementation between the highly related genes as the double knockout of PRL-1 and PRL-2 is embryonic lethal (18). PRL-2−/− mice show defects in placental development and spermatogenesis, which are accentuated with partial (heterozygotic) loss of PRL-1. In zebrafish, PRL-3 expression affects melanocyte stem cell differentiation (19).

PRLs have been implicated in many signaling pathways, reviewed in (10, 12, 20–22). The PTEN/P13K/Akt cancer pathway is the most frequently mentioned although there are papers suggesting the involvement of the Rho-family GTPase, Src, p53, STAT3/5, cKit/Notch, and Ras/MAPK pathways, among others. In the majority of studies, PRLs were proposed to act via dephosphorylation with the substrates identified from communoprecipitation experiments and changes in protein phosphorylation in cells. Confirmation of the substrates has been difficult due to the low activity of PRLs in vitro. As an example, Li et al. (23) identified phosphorylated PTEN as a substrate of PRL-2 based on communoprecipitation assays and decreased phosphorylation in cells when PRL-2 is overexpressed. However, direct measurements of phosphatase activity with purified components measured very low turnover numbers, suggesting that additional factors, such as membrane localization or unidentified cofactors, are required for full phosphatase activity (23). PRLs have also been suggested to be lipid phosphatases. Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) was dephosphorylated by PRL-3 in two different biochemical assays (24). Given the membrane localization and involvement of PRLs in the PTEN/P13K/Akt pathway, PTEN and PI(4,5)P2 are compelling substrates from a biological standpoint, but their identification requires further confirmation.

PRL structure

The first atomic structure of a PRL phosphatase (PRL-3) was solved by solution NMR in 2004 (25, 26) followed by X-ray crystal structures of PRL-1 in 2005 (27, 28). At present, almost 20 structures are known, either alone or in complexes...
the two-step catalytic cycle (Fig. 1). An aspartic acid acts both as a general acid and a base during that forms a phosphocysteine intermediate as part of the catalytic cysteine. This serves to stabilize the phosphocysteine intermediate and is a unique feature of the PRL family. The phosphocysteine intermediate has been visualized by X-ray crystallography in the CBP family phosphatase PTP1B (29).

**Defining features and phylogeny**

Within the CBP family of phosphatases, PRLs are distinguished by their farnesylation site and two features of the catalytic site: the alanine in the P-loop and the second cysteine residue (also present in DUSPs). PRLs from different species show the greatest divergence in the length of the loop between helix α3 and strand β5, which is far from the active site and unlikely to affect the distinctive catalytic properties of PRLs.

PRL phosphatases are absent in prokaryotes but occur widely in eukaryotes from unicellular organisms to mammals (30) (Fig. 1D). While many fungi species (such as *S. cerevisiae* and *C. albicans*) do not contain PRLs, their presence in algae, unicellular parasites, and some fungi points to their development early in evolution. Most vertebrates contain three PRLs. Phylogenetic analysis suggests that gene duplication occurred early as the isoforms from different vertebrates are evolutionarily more related to each other than to isoforms in the same species. The proliferation of forms also occurred independently in Leishmania and Trypanosoma protozoan parasites, which contain two or three PRL proteins, respectively.

Invertebrates generally contain only a single PRL gene. The PRL paralog in flies has received attention with recent reports that it plays developmental and protective roles in the nervous system (31–33). In worms, PRL was shown to signal through a lysosomal Ca2+ channel, TRPML (34). Leishmania and trypanosoma have multiple PRL genes, which have been suggested to contribute to the intracellular survival of the parasites (35, 36).

**Kinetics of phosphatase activity**

CBPs, including PRLs, catalyze the dephosphorylation of substrates through a two-step reaction: (i) formation of a

---

**Table 1**

| Protein/complex | Species     | PDB code | Resolution (Å) | Comments                  |
|-----------------|-------------|----------|----------------|---------------------------|
| PRL-1           | *H. sapiens*| 1XM2     | 2.7            | C104S mutant; trimeric    |
| PRL-1 (1–173)   | *R. norvegicus* | 1ZCK | 1.9            | oxidized form; trimeric   |
| PRL-1 (1–160)   | *R. norvegicus* | 1ZCL | 2.9            | C104S mutant; trimeric    |
| PRL-1 (1–160)   | *R. norvegicus* | 1X24 | 3.2            | oxidized form; trimeric   |
| PRL-1 (1–160)/peptide | *R. norvegicus* | 3RZ2 | 2.8            | oxidized form; trimeric   |
| PRL-1 (1–160)/compound 3 | *H. sapiens* | 5BX1 | 1.9            | oxidized form             |
| PRL-1 (1–173)/CBS CNNM2 | *M. musculus* | 5LXQ | 3.33           | oxidized form             |
| PRL-1 (1–173)/CBS CNNM2 | *M. musculus* | 5MMZ | 2.44           | oxidized form             |
| PRL-1 (1–160)/CBS CNNM2 | *H. sapiens* | 6WUS | 2.76           | C104D mutant              |
| PRL-2           | *H. sapiens* | 5K22     | 3.0            | reduced form              |
| PRL-2 (1–163)/CBS CNNM3 | *H. sapiens* | 5K23 | 2.96           | oxidized form             |
| PRL-2 (1–167)/CBS CNNM3 | *M. musculus* | 5K24 | 3.1            | oxidized form             |
| PRL-2 (1–163)/CBS CNNM3 | *M. musculus* | 5K25 | 3.05           | oxidized form             |
| PRL-2 (1–167)/CBS CNNM3 | *H. sapiens* | 6WUR | 2.88           | C101D mutant              |
| PRL-3           | *H. sapiens* | 1R6H     | n/a            | NMR structure             |
| PRL-3 (1–169)   | *H. sapiens* | 1V3A     | n/a            | NMR structure             |
| PRL-3 (1–162)   | *H. sapiens* | 2MBC     | n/a            | NMR structure; vanadate complex |
| PRL-3 (1–169)/CBS CNNM3 | *H. sapiens* | 5TSR | 3.19           | C104A mutant              |

*Nonmammalian PRL*  

| PRL (1–163) | *Leishmania* | 3540 | 2.3 | oxidized form |

---

Structures of PRL phosphatases
phosphoenzyme intermediate and release of the dephosphorylated substrate, and (ii) hydrolysis of phosphocysteine and release of free phosphate (Fig. 2A) (37). The two-step reaction leads to generation of a phosphoenzyme intermediate and a phenomenon known as burst kinetics. The existence of two steps has been observed in multiple CBPs but, in general, it is not detectable due to the rapid breakdown of the phosphoenzyme intermediate relative to formation ($k_3 >> k_2$). When the opposite occurs ($k_2 >> k_3$), there is an accumulation of the phosphoenzyme intermediate, which gives rise to burst kinetics: an initial burst of activity followed by a slow steady-state rate (38). The size of the burst step is stoichiometric with the amount of enzyme while the steady-state rate depends on the rate of the second step in the catalytic cycle (Fig. 2C).

PRLs are unusual in that the rate of hydrolysis of the phosphoenzyme intermediate ($k_3$) is several orders of magnitude slower than for other CBPs. Typical values for $k_3$ of protein phosphatases are in the range of 10 to 0.1 s$^{-1}$ while, for PRLs, the rate is $<1$ h$^{-1}$ (39–44). The ratio of $k_2$ divided by $k_3$ provides a measure of the burst-like character. For PRL-2, the ratio is roughly 400 compared with values of 10 or less for other CBPs. The stability of the PRL phosphoenzyme intermediate is, in part, due to the absence of serine or threonine residue in the P-loop (Fig. 1C). Replacement of the alanine (A111 in PRL-3) with serine increases the rate of steady-state catalysis, eliminating much of the burst effect (25). Conversely, when Denu et al. replaced the naturally occurring serine with alanine in VHR (vaccinia H1-related) phosphatase, the mutant enzyme showed slowed hydrolysis, which allowed the detection of phosphocysteine by NMR spectroscopy (45, 46). The strict conservation of alanine in PRLs in different species suggests that the stability of the phosphocysteine intermediate is a general feature of PRLs that has been maintained during evolution.

Although the existence of PRL burst kinetics has been known for many years (25, 27), it is often overlooked. Typical phosphatase assays use a small amount of enzyme compared with substrate, so the initial burst of phosphatase activity is small and transient. However, the existence of the burst has major consequences for the interpretation of the kinetic constants. During the steady-state condition, PRLs exhibit classical Michaelis–Menten kinetics with the extra reaction rate ($k_3$) folded into the values for the Michaelis constant ($K_M$) and $k_{cat}$ (Fig. 2C) (38). This means that it is not possible to detect the two-step kinetic cycle from simply measuring the

![Figure 2. Enzyme kinetics of PRLs.](image)

A, phosphatase activity proceeds in two steps with a phospho-enzyme intermediate ($E^*$). B, burst kinetics visualized at two different timescales. Stopped-flow traces of phosphatase activity of 3 μM PRL-2 measured with a fluorogenic substrate. Comparison of the slope of initial (inset) and steady-state curves reveals a roughly 400-fold difference in reaction rates. C, kinetic terms for a two-step enzyme mechanism (38). When the $k_3$ is larger than $k_2$, the equations simplify to the usual Michaelis–Menten kinetics. When $k_2$ is smaller, the turnover rate ($k_{cat}$) reduces to $k_2$ and the $K_M$ is decreased by the burst ratio ($k_2/k_3$). Paradoxically, the enzyme appears to have higher affinity for substrates. D, detection of the phosphoenzyme intermediate by SDS-PAGE with the Phostag reagent that slows the migration of phosphorylated proteins. PRLs become fully phosphorylated in the presence of the synthetic substrate OMFP. Phosphocysteine is hydrolyzed by boiling and dependent on the catalytic cysteine (44). E, phosphorus NMR detection of phosphocysteine in PRL-2 confirms the hours-long lifetime (44).
steady-state activity is due to the absence of a true, nonphysiological substrates (47). Low levels of phosphoenzyme intermediate formed when PRL-3 was incubated with a variety of low-molecular-weight diphosphate and triphosphate-containing compounds. This likely explains the observation that the PRLs are partially phosphorylated when purified from *E. coli*, even though the bacteria are unlikely to possess PRL-specific substrates (44, 47).

**Interactions with CNNM proteins**

A major step forward in understanding the function of PRLs was the discovery that they tightly bind CNNM (CBS-pair domain divalent metal cation transport mediators) proteins (48, 49) (Fig. 3A). CNNM proteins are membrane proteins that mediate magnesium transport and are associated with the diseases of magnesium metabolism: familial dominant hypomagnesemia (50) and Jalili syndrome (51). CNNMs have also been implicated in growth control and energy metabolism through regulation of magnesium levels (48, 49, 52). Studies of CNNM magnesium transport showed that PRL binding inhibits transport (48, 53) suggesting that PRL oncogenicity is a consequence of the growth-promoting effects of elevated cytoplasmic magnesium levels (54, 55). A role for PRLs in magnesium homeostasis was confirmed by observations that PRL levels are regulated by magnesium availability, diet, and circadian rhythms (44, 49, 56–60).

There are four CNNM proteins in humans, CNNM1, CNNM2, CNNM3, and CNNM4, composed of an uncharacterized N-terminal extracellular domain, a transmembrane DUF21 domain, a CBS-pair (cystathionine-β-synthase) domain, and cyclic nucleotide-binding homology (CNBH) C-terminal domain (61, 62). The proteins are dimers and mediate magnesium transport through the conserved

---

**Figure 3. CNNM proteins bind PRLs via the catalytic site.** A, model of PRL bound to a Mg\(^{2+}\) transporter CNNM protein. The model is based on structures of bacterial and human CNNM proteins and their complexes with PRLs (44, 47, 62, 63, 93–97). B, the PRL catalytic site controls the affinity of CNNM binding. A negative charge from either the catalytic cysteine or a substituted aspartic acid is required for high affinity (58). Oxidation or phosphorylation of the cysteine decreases or prevent binding (44). C, CNNM binding, but not phosphatase activity, is required for PRL-3 promotion of lung metastases by B16 melanoma cells (58). The PRL-3 C104D and R138E mutants are reciprocal deficient in either catalytic activity or CNNM binding while the C104E mutant is doubly deficient. D, phosphorylation of PRL-1 and -2 in vivo. The extent of phosphorylation changes in different culture media and tissues (58).

---

---

---

---
transmembrane domain. The CBS-pair domains regulate transport activity via binding of magnesium, nucleotides, and PRLs. Structurally, CBS-pair domains are composed of two CBS motifs with a mixed αβ-fold and an ATP-binding site at the dimerization interface.

**PRL–CNNM complexes**

Nine structures of complexes of PRL and CNNM CBS-pair domains have been determined (44, 47, 63) (Fig. 3A). The first structure was PRL-2 bound to the CBS-pair domain from CNNM3 and showed that binding is mediated by an extended CNNM loop that inserts into the PRL catalytic site (44). Subsequent structures with other PRLs and CBS-pair domains showed that the recognition mechanism is shared across all members of both families (Table 1). The most important binding interaction is between a CNNM aspartic acid and the PRL arginine in the P-loop. The negative charge of the aspartic acid carboxyl group mimics the phosphate group of a substrate and is positioned above the catalytic cysteine by hydrogen bonds with the positively charged arginine. Mutation of either the aspartic acid or arginine residue completely prevents binding.

Isothermal titration calorimetry measurements have shown that there is no specificity in the interactions between the different PRL and CNNM isoforms in vitro. All three PRLs bind CBS-pair domains, and the interaction loop is conserved across the four members of the CNNM family. The binding affinities are roughly 10 nM and very sensitive to modifications of the catalytic site (47, 58). Substitution of the catalytic cysteine by either alanine or serine decreases the affinity as does disulfide bond formation (47, 63) (Fig. 3B). Despite this, all the crystal structures of complexes of PRL and CNNM CBS-pair domains except one contain either mutations of the catalytic cysteine or the cysteine disulfide. This occurs because, even with a 100-fold loss of affinity, the protein concentrations used to crystallize the complexes are higher than the \( K_d \) of binding.

**Pseudophosphatase activity**

Confirmation that CNNM binding rather than phosphatase activity is responsible for some of the biological functions of PRLs required the identification of mutations that selectively inactivate phosphatase or pseudophosphatase activity. The majority of mutations in the catalytic site disrupt both functions. The PRL-3 C104S mutation has been widely used as a negative control. Finding a mutant that blocks CNNM binding was straightforward as there are protein–protein contacts outside the catalytic site that are required for binding. Finding the reciprocal mutation was more difficult, but eventually it was observed that substitution of the catalytic cysteine by aspartic acid retained binding while inactivating catalytic activity (58). Not typically considered a conservative substitution, the aspartic acid preserves the negative charge of the thiolate in the active site (Fig. 3B). Remarkably, the cysteine-to-aspartic acid mutation increases the thermal stability of PRLs by 8 to 10 °C due to relaxation of the conformational strain required to shift the cysteine pK\(_a\) in the wild-type enzyme (58).

The PRL-3 C104D mutation provided the first unambiguous evidence that PRL pseudophosphatase activity is responsible for a biological function (58). The mutant inhibited CNNM4-associated magnesium transport in cells and promoted tumor formation in a murine model of cancer metastasis (Fig. 3C). In contrast, the R138E mutation, which disrupts binding but not catalysis (with small-molecule substrates), was inactive in both assays. While the R138E mutation could disrupt PRL-3 interactions with protein substrates, the C104D mutation unequivocally shows that at least two biological functions of PRLs do not require catalytic activity. The importance of phosphatase activity versus CNNM binding for other functions should become clearer as researchers test these mutants in different cellular and animal models.

**Regulation of PRLs**

PRLs are regulated at the gene, mRNA, and protein level. A variety of transcriptional factors bind and regulate the transcription of PRL genes in response to different stimuli and growth signals, see (10). PRL-1 was first identified due to the increase in mRNA and protein levels in the liver following partial hepatectomy (4). Similarly, PRL-3 levels are dramatically increased in metastatic colon cancer (11). Of particular relevance, considering that PRLs bind magnesium transporters, is the increase in PRL protein levels in response to magnesium depletion in cultured cells (44, 49, 57–60). The change in protein levels is also accompanied by changes in the levels of cysteine phosphorylation (44, 58) (Fig. 3D).

Reactive oxygen species (ROS) have been widely studied as a mechanism of regulation of CBPs, including PRLs (3, 64, 65). The catalytic cysteine is highly susceptible to oxidation, which can lead to temporary or permanent inactivation of catalytic activity. There are five possible oxidized forms of the sulfur ranging from addition of 1, 2, or 3 oxygen atoms to sulfenamide and disulfide bond formation (66, 67). In addition, cysteine modifications by nitric oxide (S-nitrosylation) and sulphydryls (persulfidation) have been reported for some phosphatases (68, 69).

Relatively little is known about the oxidation of PRLs in cells. They are easily oxidized and form disulfides even under mildly reducing conditions in vitro (25, 27, 70). High concentrations of reducing agents are required to maintain the catalytic cysteine residue fully reduced. In cells, they are partially oxidized in addition to their extensive phosphorylation (70, 71). PRLs are particularly sensitive to inhibition by redox-active compounds that promote their oxidation or inhibit their reduction (71–73).

The biological consequences of PRL oxidation are not fully understood. Disulfide bond formation blocks both CNNM binding and catalysis, but it may also protect PRLs from overoxidation to the sulfinyl (SO\(_2\)H) or sulfonyl (SO\(_3\)H) forms (66, 67). Disulfide bond formation is reversible unlike the more oxidized states. Cysteine phosphorylation could be similarly
proteins. Much more work is needed to characterize the modifications of PRLs and CBPs in vivo.

**PRLs as molecular switches**

The formation of phosphocysteine can be thought of as a mechanism for regulating PRL activity. It is a reversible modification, changes in response to stimuli (magnesium availability) and inhibits both catalytic activity and CNNM binding. Endogenous PRLs are stably phosphorylated in cultured cells and the levels change in response to magnesium in the culture medium (44) (Fig. 3D). Unphosphorylated PRLs slowly accumulate upon magnesium withdrawal and are rapidly phosphorylated upon readdition of magnesium (44, 58). PRLs are also highly phosphorylated in tissues (58). CNNMs were recently shown to bind ARL15, a member of the ARF-like family of G proteins (74).

**Inhibitors of PRL phosphatase activity**

Due to their oncogenicity, PRLs have long been the target of searches for inhibitors (75, 76). This has not been an easy task due to the shallow catalytic pocket, low activity, and ill-defined substrate specificity. Pentamidine, an antiparasitic drug, was the first proposed inhibitor, but it is not specific or potent (35, 77). Compounds based on rhodanine, a chemical group frequently involved in nonspecific interactions, have also been developed (78, 79). Redox-active compounds such as hydrogen peroxide are effective inhibitors both in vitro and in vivo (27, 71). Thienopyridine and a related compound, JMS-053, have been proposed to be PRL-specific inhibitors although their specificity is debated due to their ability to promote oxidation (72, 73).

Compounds that block protein–protein interactions rather than catalytic activity have also been proposed. Small molecules that inhibit PRL trimerization reportedly prevent cell proliferation and migration but not phosphatase activity (80). Cai et al. (81) developed a FRET-based screening method to detect potential inhibitors of the binding of CNNM3 to PRL-2.

Surprisingly, the most promising approach has been the design of antibodies against PRL-3 for use in immunotherapy to kill PRL-3 expressing tumors (82). This unconventional approach is based on the presence of PRL-3 antigens on the cell surface, which leads to antibody-dependent cytotoxicity or phagocytosis of the tumor cells. The humanized antibody, PRL3-zumab, reduced tumor relapse in an animal model and has been approved for Phase 2 clinical trials against solid tumors in Singapore, United States, and China (83).

**Perspectives and conclusions**

There are many unanswered questions about the biological function of PRLs but also signs that the gaps in our understanding are closing. One promising development is the realization that CNNM proteins are associated with another family of proteins, the melastatin-related transient receptor potential ion channels, TRPM6 and TRPM7 (61, 84–87). Like CNNMs, TRPM6/7 are important for magnesium homeostasis and have been implicated in cancer (55, 88–90). The convergence of these two well-established research fields promises new insights.

Finally, while many groups still consider PRLs to function primarily as phosphatases, there is increasing acceptance that PRLs also act as pseudophosphatases and that the two activities are inherently linked. CNNM binding blocks PRL catalytic activity and PRL catalytic activity generates the phosphoenzyme intermediate that is unable to bind CNNMs. Identifying the mechanisms that link these to magnesium levels and cell signaling pathways are key challenges for the future.

**Acknowledgements**—This work was supported by funding from the Canadian Natural Sciences and Engineering Research Council, the Canadian Institutes of Health Research, and the Canada Research Chairs Program.

**Author contributions**—G. K., M. Y., and R. F. writing—original draft; K. G. writing—review and editing.

**Conflict of interest**—The authors declare that they have no conflicts of interest with the contents of this article.

**Abbreviations**—The abbreviations used are: CBP, cysteine-based phosphatase; CBS, cystathionine-β-synthase; CDC14, cell division cycle 14; DUSP, dual-specificity phosphatase; PRL, Phosphatase of regenerating liver; PTP, protein tyrosine phosphatase.

**References**

1. Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., and Mustelin, T. (2004) Protein tyrosine phosphatases in the human genome. Cell 117, 699–711.
2. Chen, M. J., Dixon, J. E., and Manning, G. (2017) Genomics and evolution of protein phosphatases. *Sci. Signal.* 10, eaag1796
3. Tonks, N. K. (2006) Protein tyrosine phosphatases: From genes, to function, to disease. *Nat. Rev. Mol. Cell Biol.* 7, 833–846
4. Diamond, R. H., Cressman, D. E., Laz, T. M., Abrams, C. S., and Taub, R. (1994) PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth. *Mol. Cell. Biol.* 14, 3752–3762
5. Cates, C. A., Michael, R. L., Stayrook, K. R., Harvey, K. A., Burke, Y. D., Randall, S. K., Crowell, P. L., and Crowell, D. N. (1996) Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases. *Cancer Lett.* 110, 49–55
6. Zeng, Q., Hong, W., and Tan, Y. H. (1998) Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1. *Biochem. Biophys. Res. Commun.* 244, 421–427
7. Zeng, Q., Si, X., Horstmann, H., Xu, Y., Hong, W., and Pallen, C. J. (2000) Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2 and -3 with the plasma membrane and the early endosome. *J. Biol. Chem.* 275, 21444–21452
8. Gjorloff-Wingren, A., Saxena, M., Han, S., Wang, X., Alonso, A., Renedo, M., Oh, P., Williams, S., Schnitzer, J., and Mustelin, T. (2000) Subcellular localization of intracellular protein tyrosine phosphatases in T cells. *Eur. J. Immunol.* 30, 2412–2421
9. Sun, J. P., Luo, Y., Yu, X., Wang, W. Q., Zhou, B., Liang, F., and Zhang, Z. Y. (2007) Phosphatase activity, trimerization, and the C-terminal polybasic region are all required for PRL1-mediated cell growth and migration. *J. Biol. Chem.* 282, 29043–29051
10. Hardy, S., Kostantin, E., Hatzihiristidis, T., Zolotarov, Y., Uetani, N., and Tremblay, M. L. (2018) Physiological and oncogenic roles of the PRL phosphatases. *FEBS J.* 285, 3886–3908
11. Saha, S., Bardelli, A., Buckhaults, P., Velculescu, V. E., Rago, C., St Croix, B., Romans, K. E., Choti, M. A., Lengauer, C., Kinzler, K. W., and...
Vogelstein, B. (2001) A phosphatase associated with metastasis of colorectal cancer. Science 294, 1343–1346

12. Campbell, A. M., and Zhang, Z. Y. (2014) Phosphatase of regenerating liver: A novel target for cancer therapy. Expert Opin. Ther. Targets 18, 555–569

13. Dong, Y., Zhang, L., Zhang, S., Bai, Y., Chen, H., Sun, X., Yong, W., Li, W., Colvin, S. C., Rhodes, S. I., Shou, W., and Zhang, Z. Y. (2012) Phosphatase of regenerating liver 2 (PRL2) is essential for placental development by down-regulating PTEN (Phosphatase and Tensin Homologue Deleted on Chromosome 10) and activating Akt protein. J. Biol. Chem. 287, 32172–32179

14. Bai, Y., Zhou, H. M., Zhang, L., Dong, Y., Zeng, Q., Shou, W., and Zhang, Z. Y. (2016) Role of phosphatase of regenerating liver 1 (PRL1) in spermatogenesis. Sci. Rep. 6, 34211

15. Yan, H., Kong, D., Ge, X., Gao, X., and Han, X. (2011) Generation of conditional knockout alleles for PRL-3. J. Biomed. Res. 25, 438–443

16. Zimmerman, M. W., Homanics, G. E., and Lazo, J. S. (2013) Targeted deletion of the metastasis-associated phosphatase Ptp4a3 (PRL-3) suppresses murine colon cancer. PLoS One 8, e58300

17. Sacchetti, C., Bai, Y., Stanford, S. M., Di Benedetto, P., Cipriani, P., Santelli, E., Piera-Velazquez, S., Chemistkiy, V., Kiosses, W. B., Ceponis, A., Kaestner, K. H., Boin, F., Jimenez, S. A., Giacomelli, R., Zhang, Z. Y., et al. (2017) PTP4A1 promotes TGFbeta signaling and fibrosis in systemic sclerosis. Nat. Commun. 8, 1060

18. Dong, Y., Zhang, L., Bai, Y., Zhou, H. M., Campbell, A. M., Chen, H., Yong, W., Zhang, W., Zeng, Q., Shou, W., and Zhang, Z. Y. (2014) Phosphatase of regenerating liver 2 (PRL2) deficiency impairs kit signaling and spermatogenesis. J. Biol. Chem. 289, 3799–3810

19. Johansson, J. A., Marie, K. L., Lu, Y., Brombin, A., Santoriello, C., Zeng, Z., Zich, J., Gautier, P., von Kriegsheim, A., Brunsdon, H., Wheeler, A. P., Dreger, M., Houston, D. R., Dooley, C. M., Sims, A. H., et al. (2020) PRL3-DDX21 transcriptional control of endolysosomal genes restricts melanocyte stem cell differentiation. Dev. Cell 54, 317–332.e9

20. Nio, T., and Kohn, M. (2016) Regulatory mechanisms of phosphatase of regenerating liver (PRL)-3. Biochem. Soc. Trans. 44, 1305–1312

21. Duciel, L., Monraz Gomez, L. C., Kondratova, M., Kuperstein, I., and Soulat, D. (2017) Characterization of the protein tyrosine phosphatase LmPRL-1 secreted by Leishmania major via the exosome pathway. Infect. Immunity. 85, e00884–17

22. Denu, J. M., Stuckey, J. A., Saper, M. A., and Dixon, J. E. (1996) Form and function in protein dephosphorylation. Cell 87, 361–364

23. Johnson, K. A. (1992) Transient-state kinetic analysis of enzyme reaction pathways. In: Sigman, D. S., ed. The Enzymes, 3rd Ed., Academic Press, Cambridge, Massachusetts: 1–61

24. Gottlin, E. B., Xu, X., Epstein, D. M., Burke, S. P., Eckstein, J. W., Ballou, D. P., and Dixon, J. E. (1996) Kinetic analysis of the catalytic domain of human cdc25B. J. Biol. Chem. 271, 27445–27449

25. Zhang, Z. Y., and VanEtten, R. L. (1991) Pre-steady state and steady-state kinetic analysis of the low molecular weight phosphotyrosyl protein phosphatase from bovine heart. J. Biol. Chem. 266, 1516–1525

26. Zhang, Z. Y., Zhou, G., Denu, J. M., Wu, L., Tang, X., Mondesert, O., Russell, P., Butch, E., and Guan, K. L. (1995) Purification and characterization of the low molecular weight protein tyrosine phosphatase, Stpl1, from the fission yeast Schizosaccharomyces pombe. Biochemistry 34, 10560–10568

27. Wang, J., and Walsh, C. T. (1997) Mechanistic studies on full length and the catalytic domain of the tandem SH2 domain-containing protein tyrosine phosphatase: Analysis of phosphoenzyme levels and Vmax stimulatory effects of glycerol and of a phosphotyrosyl peptide ligand. Biochemistry 36, 2993–2999

28. Zhang, Z. Y. (1995) Kinetic and mechanistic characterization of a mammalian protein-tyrosine phosphatase, PTP1. J. Biol. Chem. 270, 11199–11204

29. Guleria, I., Funato, Y., Wu, H., Yang, M., Kozlov, G., Mikhi, H., and Gehring, K. (2016) Phosphocysteine in the PRL-CNNM pathway mediates magnesium homeostasis. EMBO Rep. 17, 1890–1900

30. Denu, J. M., and Dixon, J. E. (1995) A catalytic mechanism for the dual-specific phosphatases. Proc. Natl. Acad. Sci. U. S. A. 92, 5910–5914

31. Denu, J. M., Lohse, D. L., Vijayalakshmi, J., Saper, M. A., and Dixon, J. E. (1996) Visualization of intermediate and transition-state structures in protein-tyrosine phosphatase catalysis. Proc. Natl. Acad. Sci. U. S. A. 93, 2493–2498

32. Zhang, H., Kozlov, G., Li, X., Wu, H., Guleria, I., and Gehring, K. (2017) PRL3 phosphatase active site is required for binding the putative magnesium transporter CNNM3. Sci. Rep. 7, 48

33. Funato, Y., Yamazaki, D., Mizukami, S., Du, L., Kikuchi, K., and Mikhi, H. (2014) Membrane protein CNNM4-dependent Mg2+ efflux suppresses tumor progression. J. Clin. Invest. 124, 5398–5410

34. Hardy, S., Uetani, N., Wong, N., Kostantin, E., Labbe, D. P., Begin, L. R., Mes-Masson, A., Miranda-Saavedra, D., and Tremblay, M. L. (2015) The JBC REVIEWS: The double lives of PRL phosphatases
protein tyrosine phosphatase PRL-2 interacts with the magnesium transporter CNNM3 to promote oncogenesis. *Oncogene* **34**, 986–995

50. Stuiver, M., Lainez, S., Will, C., Teryn, S., Gunzel, D., Debaix, H., Sommer, K., Kopplin, K., Thumfart, J., Kampik, N. B., Querfeld, U., Willnow, T. E., Nemec, V., Wagner, C. A., Hoenderop, J. G., et al. (2011) CNNM2, encoding a basolateral protein required for renal Mg2+ handling, is mutated in dominant hypomagnesemia. *Am. J. Hum. Genet.* **88**, 333–343

51. Parry, D. A., Mighell, A. J., El-Sayed, W., Shore, R. C., Jalili, I. K., Dollfus, H., Bloch-Zupan, A., Carr, R. I., Downey, L. M., Blain, K. M., Mansfield, D. C., Shahrami, M., Heidari, M., Aref, P., et al. (2009) Mutations in CNNM4 cause Jalili syndrome, consisting of autosomal-recessive cone-rod dystrophy and amelogenesis imperfecta. *Am. J. Hum. Genet.* **84**, 266–273

52. Yamazaki, D., Funato, Y., Miura, J., Sato, S., Toyosawa, S., Furutani, K., Kurachi, Y., Omori, Y., Furukawa, T., Tsuda, T., Kuwabata, S., Mizukami, S., Kikuchi, K., and Miki, H. (2013) Basolateral Mg2+ extrusion via CNNM4 mediates transcellular Mg2+ transport across epithelia: A mouse model. *PLoS Genet.* **9**, e1003983

53. Hirata, Y., Funato, Y., Takano, Y., and Miki, H. (2014) Mg2+–dependent interactions of ATP with the cystathionine-beta-synthase (CBS) domains of a magnesium transporter. *J. Biol. Chem.* **289**, 14731–14739

54. Rubin, H. (2007) The logic of the Membrane, Magnesium, Mitosis (M3M) model for the regulation of animal cell proliferation. *Arch. Biochem. Biophys.* **458**, 16–23

55. Trapani, V., and Wolf, F. I. (2019) Dysregulation of Mg(2+) homeostasis contributes to acquisition of cancer hallmarks. *Cell Calcium* **83**, 102078

56. Uetani, N., Hardy, S., Gravel, S. P., Kiessling, S., Pietrobon, A., Wong, N. Y., Konrad, M., Bindels, R. J., and Hoenderop, J. G., et al. (2014) CNNM2, encoding a basolateral protein required for renal Mg2+ handling, is mutated in dominant hypomagnesemia. *PLoS Genet.* **10**, 791–799

57. Gungabeesoon, J., Tremblay, M. L., and Uetani, N. (2016) Localizing PRL phosphatase expression to mediate interactions of ATP with the cystathionine-beta-synthase (CBS) domains of a magnesium transporter. *J. Biol. Chem.* **289**, 14731–14739

58. Koziol, G., Funato, Y., Chen, Y. S., Zhang, Z., Illes, K., Miki, H., and Gehring, K. (2020) PRL3 pseudophosphatase activity is necessary and sufficient to promote metastatic growth. *J. Biol. Chem.* **295**, 11682–11692

59. Hardy, S., Kostantin, E., Wang, S. J., Hristova, T., Galicia-Vazquez, G., Yoshida, A., Funato, Y., and Miki, H. (2018) Phosphatase of regenerating liver maintains cellular magnesium homeostasis. *J. Biochem.* **165**, 219–225

60. Gimenez-Mascarell, P., Gonzalez-Recio, I., Fernandez-Rodriguez, C., Oyarte, I., Muller, D., Martinez-Chantar, M. L., and Martinez-Cruz, L. A. (2019) Current structural knowledge on the CNNM family of magnesium transport mediators. *Int. J. Mol. Sci.* **20**, 1135

61. Dustin, C. M., Heppner, D. E., Lin, M. J., and van der Vliet, A. (2020) Redox regulation of tyrosine kinase signalling: More than meets the eye. *J. Biol. Chem.* **167**, 151–163

62. Miki, H., and Funato, Y. (2012) Regulation of intracellular signalling through cysteine oxidation by reactive oxygen species. *J. Biochem.* **151**, 255–261

63. Salmeen, A., and Barford, D. (2005) Functions and mechanisms of redox regulation of cysteine-based phosphatases. *Antioxid. Redox Signal.* **7**, 560–577

64. Heneberg, P. (2014) Reactive nitrogen species and hydrogen sulfide as regulators of protein tyrosine phosphatase activity. *Antioxid. Redox Signal.* **20**, 2191–2209

65. Döka, E., Ida, T., Dagnell, M., Abiko, Y., Luong, N. C., Balog, N., Takata, T., Espinoza, B., Nishimura, A., Cheng, Q., Funato, Y., Miki, H., Fukuto, J. M., Prigge, J. R., Schmidt, E. E., et al. (2020) Control of protein function through oxidation and reduction of persulfated states. *Sci. Adv.* **6**, eaaa3858

66. Skinner, A. L., Vartia, A. A., Williams, T. D., and Laurence, J. S. (2009) Enzyme activity of phosphatase of regenerating liver is controlled by the redox environment and its C-terminal residues. *Biochemistry* **48**, 4262–4272

67. Ishii, T., Funato, Y., and Miki, H. (2013) Thioredoxin-related protein 32 (TRP32) specifically reduces oxidized phosphatase of regenerating liver (PRL). *J. Biol. Chem.* **288**, 7263–7270

68. Dustin, C. M., Heppner, D. E., Lin, M. J., and van der Vliet, A. (2020) RHOM3 contributes to acquisition of cancer hallmarks. *PLoS Genet.* **16**, e1003983

69. Koziol, G., Funato, Y., Chen, Y. S., Zhang, Z., Illes, K., Miki, H., and Gehring, K. (2020) PRL3 pseudophosphatase activity is necessary and sufficient to promote metastatic growth. *J. Biol. Chem.* **295**, 11682–11692

70. Hardy, S., Kostantin, E., Wang, S. J., Hristova, T., Galicia-Vazquez, G., Baranov, P. V., Pelletier, J., and Tremblay, M. L. (2019) Magnesium-sensitive upstream ORF controls PRL phosphatase expression to mediate energy metabolism. *Proc. Natl. Acad. Sci. U. S. A.* **116**, 2925–2934

71. Yoshida, A., Funato, Y., and Miki, H. (2018) Phosphatase of regenerating liver maintains cellular magnesium homeostasis. *Biochem. J.* **475**, 1129–1139

72. Pathak, M. K., Dhawan, D., Lindner, D. J., Borden, E. C., Farver, C., and Yi, T. (2002) Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. *Mol. Cancer Ther.* **1**, 1255–1264

73. AHN, J. H., Kim, S. J., Park, W. S., Cho, S. Y., Ha, J. D., Kim, S. M., Kang, S. K., Jeong, J. G., Jung, S. K., Lee, S. H., Kim, H. M., Park, S. K., Lee, K. H., Lee, C. W., Ryu, S. E.,e et al. (2006) Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors. *Bioorg. Med. Chem. Lett.* **16**, 2996–2999

74. Min, G., Lee, S. K., Kim, H. N., Han, Y. M., Lee, R. H., Jeong, D. G., Han, C. D., and Kwon, B. M. (2013) Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells. *Bioorg. Med. Chem. Lett.* **23**, 3769–3774

75. Bai, Y., Yu, Z. H., Liu, S., Zhang, L., Zhang, R. Y., Zeng, L. F., Zeng, S., and Zhang, Z. Y. (2016) Novel anticancer agents based on targeting the trimer interface of the PRL phosphatase. *Antioxid. Redox Signal.* **20**, 4805–4815

76. Thura, M., Al-Aidaroso, A. Q., Gupta, A., Chee, C. E., Lee, S. C., Hui, K. M., Li, J., Guam, Y., Yong, W. P., So, J., Cheng, W. J., Ng, C. H., Zhou, I., Wang, L. Z., Yuen, J. S. P., et al. (2019) PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein. *Nat. Commun.* **10**, 2484

77. Thura, M., Ye, Z., Al-Aidaroso, A. Q., Xiong, Q., Ong, J. Y., Gupta, A., Li, J., Guo, K., Ang, K. H., and Zeng, Q. (2021) PRL3 induces polypoid giant cancer cells by regulating PRL3-zumab to reduce tumor relapse. *Compr. Biol. Chem.* **40**, 6923

78. Arjona, F. J., de Bajaj, J. H., Schlingmann, K. P., Lameris, A. L., van Wijk, E., Flik, G., Regele, S., Korenke, G. C., Neophytou, B., Rust, S., Reintjes, N., Konrad, M., Bindels, R. J., and Hoenderop, J. G. (2014) CNNM2 mutations cause impaired brain development and seizures in patients with hypomagnesemia. *PloS Genet.* **10**, e1004267

79. Bates-Williams, C., Sah, R., and Clapham, D. E. (2011) TRPM7, the Mg(2+) inhibited channel and kinase. *Adv. Exp. Med. Biol.* **704**, 173–183
86. Funato, Y., Yamazaki, D., Okuzaki, D., Yamamoto, N., and Miki, H. (2021) Importance of the renal ion channel TRPM6 in the circadian secretion of renin to raise blood pressure. *Nat. Commun.* **12**, 3683

87. Kollewe, A., Chubanov, V., Tseung, F. T., Correia, L., Schmidt, E., Rössig, A., Zierler, S., Haupt, A., Müller, C. S., Bildl, W., Schulte, U., Nicke, A., Fakler, B., and Gudermann, T. (2021) The molecular appearance of native TRPM7 channel complexes identified by high-resolution proteomics. *eLife* **10**, e68544

88. Dhennin-Duthille, I., Gautier, M., Korichneva, I., and Ouadid-Ahidouch, H. (2014) TRPM7 involvement in cancer: A potential prognostic factor. *Magnes. Res.* **27**, 103–112

89. Chubanov, V., Mittermeier, L., and Gudermann, T. (2018) Role of kinase-coupled TRP channels in mineral homeostasis. *Pharmacol. Ther.* **184**, 159–176

90. Meng, S., Alanazi, R., Ji, D., Bandura, J., Luo, Z. W., Fleig, A., Feng, Z. P., and Sun, H. S. (2021) Role of TRPM7 kinase in cancer. *Cell Calcium* **96**, 102400

91. Zhang, Z. Y., Wang, Y., and Dixon, J. E. (1994) Dissecting the catalytic mechanism of protein-tyrosine phosphatases. *Proc. Natl. Acad. Sci. U. S. A.* **91**, 1624–1627

92. Denu, J. M., and Dixon, J. E. (1998) Protein tyrosine phosphatases: Mechanisms of catalysis and regulation. *Curr. Opin. Chem. Biol.* **2**, 633–641

93. Chen, Y. S., Kozlov, G., Fakih, R., Yang, M., Zhang, Z., Kovrigin, E. L., and Gehring, K. (2020) Mg(2+)-ATP sensing in CNNM, a putative magnesium transporter. *Structure* **28**, 324–335.e4

94. Huang, Y., Jin, F., Funato, Y., Xu, Z., Zhu, W., Wang, J., Sun, M., Zhao, Y., Yu, Y., Miki, H., and Hattori, M. (2021) Structural basis for the Mg(2+) recognition and regulation of the CorC Mg(2+) transporter. *Sci. Adv.*, eabe6140

95. Chen, Y. S., Kozlov, G., Fakih, R., Funato, Y., Miki, H., and Gehring, K. (2018) The cyclic nucleotide–binding homology domain of the integral membrane protein CNNM mediates dimerization and is required for Mg2+ efflux activity. *J. Biol. Chem.* **293**, 19998–20007

96. Corral-Rodriguez, M. A., Stuiver, M., Abascal-Palacios, G., Diercks, T., Oyenarte, I., Ereno-Orbea, J., de Opakua, A. L., Blanco, F. J., Encinar, J. A., Spiwok, V., Terashima, H., Accardi, A., Muller, D., and Martinez-Cruz, L. A. (2014) Nucleotide binding triggers a conformational change of the CBS module of the magnesium transporter CNNM2 from a twisted towards a flat structure. *Biochem. J.* **464**, 23–34

97. Chen, Y. S., Kozlov, G., Moeller, B. E., Rohaim, A., Fakih, R., Roux, B., Burke, J. E., and Gehring, K. (2021) Crystal structure of an archaeal CorB magnesium transporter. *Nat. Commun.* **12**, 4028